Clinical Features and Outcomes of Severe Acute Respiratory Syndrome and Predictive Factors for Acute Respiratory Distress Syndrome

Cheng-Yu Chen,^1,5 Chen-Hsen Lee,^5 Cheng-Yi Liu,^5 Jia-Horng Wang,^3,6 Lee-Min Wang,^4,6 Reury-Perng Perng^1,6*

^1Chest Department, ^2Division of Infection, Department of Medicine, ^3Department of Respiratory Therapy, ^4Emergency Department, Taipei Veterans General Hospital, and ^6Institute of Emergency and Critical Medicine, and ^5National Yang-Ming University School of Medicine, Taipei, Taiwan, R.O.C.

Background: Severe acute respiratory syndrome (SARS) is an emerging infectious disease, and indeed, the SARS epidemic in Taiwan from March to July 2003 had a great impact. This study depicts the clinical characteristics and short-term outcomes of patients with SARS treated at Taipei Veterans General Hospital; potential predictive factors for acute respiratory distress syndrome (ARDS) are also analyzed.

Methods: This study retrospectively analyzed data for 67 SARS patients, who were grouped according to whether or not ARDS developed during the clinical course of SARS.

Results: There were 32 males (mean age, 50.3 years; range, 20–75 years) and 35 females (mean age, 51.1 years; range, 23–86 years). Twenty-five patients (37.3%) were health care workers. At admission, 50 patients (74.6%) had abnormal chest radiographs, and all patients developed pulmonary infiltrates during the following week. During hospitalization, lymphopenia was found in 57 patients (85.1%); and elevated levels of lactate dehydrogenase (LDH; n = 55; 83.3%), C-reactive protein (n = 55; 83.3%), aminotransferases (n = 44; 65.7%), and creatine kinase (n = 14; 20.9%) were also noted. ARDS developed in 33 patients (49.3%), who were generally older than the patients in whom ARDS did not develop, male, non-health care workers, and who generally had dyspnea at the time of diagnosis, and a history of diabetes mellitus, hypertension or cerebrovascular accident. Patients with, versus those without, ARDS also tended to present with more severe lymphopenia and leukocytosis, and with higher levels of LDH and aspartate aminotransferase. The overall mortality rate was 31.3% (21/67), whereas the rate for patients who developed ARDS was 63.6% (21/33). Multivariate analyses showed that age greater than 65 years (odds ratio, OR, 10.6; 95% confidence interval, CI, 2.1–54.1), pre-existing diabetes mellitus (OR, 13.7; 95% CI, 1.3–146.9), and elevated levels of LDH (OR, 8.4; 95% CI, 1.9–36.9) at admission, were independent predictors of ARDS.

Conclusion: The clinical manifestations of SARS showed high variability, and were related to the underlying health status of individual patients. Importantly, the development of ARDS was associated with significant mortality, despite aggressive therapy. [J Chin Med Assoc 2005;68(1):4–10]

Key Words: acute respiratory distress syndrome, pneumonia, severe acute respiratory syndrome

Introduction

Severe acute respiratory syndrome (SARS) is an infectious pulmonary disease that appears to have originated in southern China in the fall of 2002. The disease then spread to other parts of Asia, Europe and North America, with more than 8,000 cases now reported worldwide. The first two SARS cases in Taiwan were diagnosed in a couple on March 14, 2003; the man had traveled to Guangdong Province and Hong Kong in February 2003. The couple was treated successfully in an intensive...
Severe acute respiratory syndrome in Taiwan

care unit (ICU) at medical center A. Subsequently, most SARS patients were treated at that medical center, until two clusters of cases were noted in late April, 2003, in Taipei. The origin of the outbreak was a laundry worker, aged 42 years, with diabetes mellitus, who was employed at hospital B. As the index patient had been symptomatic for 6 days before SARS was diagnosed, the number of potentially exposed persons was estimated to be 10,000 patients and visitors, and 930 staff. Within less than 2 weeks, another outbreak of SARS clusters occurred in hospital C, which is near hospital B. Taipei Veterans General Hospital undertook the care of critically ill SARS patients, who were mainly transferred from hospital B and hospital C.

The cause of SARS is a novel coronavirus. Natural clinical histories have ranged from febrile respiratory symptoms, without hypoxemia, to respiratory distress requiring intubation and, occasionally, resulting in death. Worldwide, the substantial mortality associated with SARS has varied markedly from 15–27%. This paper provides a retrospective review of predictive factors for acute respiratory distress syndrome (ARDS) in patients with SARS treated at Taipei Veterans General Hospital.

Methods

Clinical diagnostic criteria
The following criteria were used to evaluate the probability of SARS:

1. A history of close contact with a SARS patient, or evidence of traveling to SARS-endemic areas within 10 days before symptom onset.
2. Acute onset of fever > 38°C.
3. Respiratory symptoms, including cough or dyspnea.
4. Chest radiograph showing patchy or spotty pulmonary infiltrates.
5. ARDS without an identifiable cause.

Treatment
All patients were isolated for treatment, which included antibiotics to prevent secondary bacterial infection. The choice of antibiotics was based on empirical knowledge of the common atypical pathogens encountered in the community. Other antibiotics were administered to patients with established bacterial infection according to the results of drug-sensitivity testing after bacterial culture. The administration of ribavirin, intravenous immunoglobulin or corticosteroids was determined by physicians. Patients were intubated when respiratory failure developed, i.e. PaO$_2$ < 90% during the administration of 100% supplemental oxygen with or without a respiratory rate of more than 35 breaths per minute.

Study patients
This study included all patients with SARS admitted to Taipei Veterans General Hospital between March 20 and July 5, 2003, even though 14 cases in our cohort were reported previously by Chiang et al. Thirty-three patients were referred due to evidence of SARS noted at another hospital. These patients were categorized according to the most severe clinical condition, i.e. non-ARDS or ARDS, with ARDS defined according to the American-European consensus conference:

1. Non-ARDS: patients with a ratio of partial arterial oxygen pressure (PaO$_2$)/fractional inspired oxygen (FIO$_2$) > 200 mmHg, and who did not develop ARDS during their stay in the ward.
2. ARDS: patients with PaO$_2$/FIO$_2$ ≤ 200 mmHg, and with bilateral lung infiltrates at admission or during their stay in the ward.
Statistical analysis
We compared differences in epidemiologic, clinical, and laboratory measures between patients who developed ARDS and those who did not. Square-root transformation was performed, for CBCs and biochemical parameters, for the normality of data. The Kolmogorov-Smirnov test was used to check normality. The Student’s t test was adapted to normal-distribution data. For continuous variables not fitted to a normal distribution, median and interquartile ranges (IQRs) were calculated as summaries of distribution, and a Wilcoxon rank-sum test was adapted for comparison. A Chi-squared test was used to compare the category variables. For calculating the odds ratio of ARDS in the logistic regression analysis, each variable was dichotomized using a “normal-limits” value as cut-off (except for CRP [cut-off, 5 mg/L] and age [65 years]). To dichotomize the variable “comorbidities”, the study group was divided into patients with (value of 1) or without underlying disease (value of 0). A p value of less than 0.05 was considered statistically significant. All analyses were carried out using Statistical Package for the Social Sciences version 11.0 (SPSS Inc, Chicago, IL, USA).

Results
Demographics and clinical information
A total of 67 patients with SARS were admitted to our hospital between March 20 and July 5, 2003, which represented 10% (67 of 668) of all documented, probable SARS cases in Taiwan. The patients comprised 32 men and 35 women; mean age ± standard deviation (SD) was 51.0 ± 21.9 years (range, 23–86 years) (Table 1). Twenty-five patients (37.3%) were medical professionals and the others had various occupations. Thirty-three (49.3%) patients required mechanical ventilatory support.

Patients without ARDS were significantly younger than patients with ARDS (39.1 ± 16.5 years vs 63.4 ± 20.0 years). All patients received nasopharyngeal-swab RT-PCR tests routinely on days 1 and 7 of hospitalization, and only 22 patients (32.8%) had positive findings. Thirty-three patients had assays for anti-SARS-CoV antibodies on day 21 of hospitalization; 28 of them (84.8%) had positive findings. The most common initial clinical symptoms were fever (95.5% of patients), cough (65.7%) and dyspnea (49.3%); watery diarrhea was noted in less than 20% of patients. Forty-two patients (62.7%) had other comorbid conditions, which principally included diabetes mellitus (n = 16), viral hepatitis (n = 12), hypertension (n = 13), and cerebrovascular accident (CVA; n = 8). Levoﬂoxacin was used in a total of 49 patients (73.1%), whereas other antibiotics were used significantly more frequently in patients with ARDS rather than in those without (26 vs 17; p = 0.021). The administration of ribavirin, intravenous immunoglobulin or corticosteroids did not differ signiﬁcantly between patients with ARDS and those without, although pulse corticosteroid therapy (methylprednisolone 500 mg intravenously other 12 hours for 2–3 days) was given to four patients with ARDS versus none of the non-ARDS patients (p = 0.053). The mean length of hospital stay was significantly shorter for patients without ARDS than for survivors of ARDS (19.8 days vs 39.3 days; p < 0.001) (Table 1).

The overall mortality rate was 31.3% (21 of 67 patients), whereas the mortality rate for patients who underwent mechanical ventilation was 63.6% (21 of 33).

Laboratory data
Laboratory indices during hospitalization are summarized in Table 2. Sixteen patients (23.9%) had a leukocyte count < 3,500/mm³, 57 (85.1%) had a lymphocyte count < 1,000/mm³, and 15 (22.4%) had a platelet count < 100,000/mm³. CK levels increased to > 200 U/L in 14 of 67 patients (20.9%) and, among a group of 66 evaluable patients, elevated levels of the following parameters were noted: AST > 45 U/L in 42 patients (63.6%); LDH > 213 U/L in 55 (83.3%); and a CRP increase of up to 1 mg/dL in 55 patients (83.3%), and of up to 5 mg/L in 41 (62.1%).

Radiographic findings
Chest radiographs revealed changes relating to pneumonia, although 17 patients (25.4%) did not have pulmonary infiltrates at initial radiograph. Combined central and peripheral lesions were evident in most patients, and most had rapid progression from a single localized lesion. The most common locations were the bilateral lower lung regions (Table 3). In the 17 patients with an initial normal radiograph, and who subsequently developed consolidation, the average time from fever onset to an abnormal radiograph was 4.6 ± 6.8 days (range, 1–13 days).

Predictive factors for ARDS
We used a logistic multiple regression model to uncover risk factors for the development of ARDS. This model included LDH, CRP, age more than 65 years, diabetes mellitus, hypertension, previous CVA, and male gender, from univariate logistic regression analyses. Odds ratios for ARDS development in the 67 patients with SARS
Table 1. Characteristics of SARS patients at Taipei Veterans General Hospital

|                      | Non-ARDS (n = 34) | ARDS (n = 33) | Total (n = 67) | \(p^*\) |
|----------------------|-------------------|---------------|---------------|---------|
| **Age (yr), mean (range)** | 39.1 (23–76)      | 63.4 (27–86)  | 51.0 (23–86)  | < 0.001 |
| **Male gender, n (%)** | 35.3              | 60.6          | 47.8          | 0.038   |
| **Health care workers, n (%)** | 50.0              | 24.2          | 37.3          | 0.029   |
| **Positive RT-PCR for SARS, n (%)** | 17 (50.0)         | 16 (48.5)     | 22 (32.8)     | 0.010   |
| **Positive for anti-SARS-CoV antibodies**, n (%) | 17/17 (100)       | 11/16 (68.8)  | 28/33 (84.8)  | 0.018   |
| **Symptoms, n (%)** |                   |               |               |         |
| Fever                | 34 (100)          | 30 (90.9)     | 64 (95.5)     | 0.114   |
| Cough                | 21 (61.8)         | 23 (69.7)     | 44 (65.7)     | 0.494   |
| Dry                  | 17 (50.0)         | 18 (54.5)     | 35 (52.2)     | 0.710   |
| Productive           | 4 (11.8)          | 5 (15.2)      | 9 (13.4)      | 0.734   |
| Dyspnea              | 9 (26.5)          | 24 (72.7)     | 33 (49.3)     | < 0.001 |
| Diarrhea             | 7 (20.6)          | 5 (15.2)      | 12 (17.9)     | 0.562   |
| Malaise              | 6 (17.6)          | 3 (9.1)       | 9 (13.4)      | 0.476   |
| Myalgia/arthritis    | 7 (20.6)          | 2 (6.1)       | 9 (13.4)      | 0.150   |
| **Comorbidities, n (%)** |                   |               |               |         |
| Diabetes mellitus    | 1 (2.9)           | 15 (45.5)     | 16 (23.9)     | < 0.001 |
| HBV carrier          | 9 (26.5)          | 3 (9.1)       | 12 (17.9)     | 0.109   |
| Hypertension         | 3 (8.8)           | 10 (30.3)     | 13 (19.4)     | 0.035   |
| CVA                  | 1 (2.9)           | 7 (21.2)      | 8 (11.9)      | 0.027   |
| HCV infection        | 2 (5.9)           | 3 (9.1)       | 5 (7.5)       | 0.673   |
| Old pulmonary TB     | 3 (8.8)           | 2 (6.1)       | 5 (7.5)       | 0.667   |
| COPD or asthma       | 1 (2.9)           | 3 (9.1)       | 4 (6.0)       | 0.356   |
| Cardiac disease      | 3 (8.8)           | 4 (12.1)      | 7 (10.4)      | 0.709   |
| Thyroid disease      | 1 (2.9)           | 1 (3.0)       | 2 (3.0)       | 0.983   |
| **Treatment, n (%)** |                   |               |               |         |
| Levofloxacin         | 29 (85.3)         | 20 (60.6)     | 49 (73.1)     | 0.029   |
| Other antibiotics*   | 17 (50.0)         | 26 (78.8)     | 43 (64.2)     | 0.021   |
| Ribavirin            | 16 (47.1)         | 19 (57.6)     | 35 (52.2)     | 0.466   |
| IVIG                 | 18 (52.9)         | 19 (57.6)     | 37 (55.2)     | 0.807   |
| Non-pulse corticosteroid | 19 (55.9)       | 21 (63.6)     | 40 (59.7)     | 0.621   |
| Pulse corticosteroid | 0 (0)             | 4 (12.1)      | 4 (6.0)       | 0.053   |
| **Mean length of hospital stay, d (IQR)** | 19.8 (11.0–24.3) | 39.3 (29.0–50.0) | 24.9 (14.8–33.3) | < 0.001 |

*ARDS vs non-ARDS; †33 patients received assays for anti-SARS-CoV antibodies on day 1 and all 27 patients received enzyme-linked immunosorbent assay for IgM and IgG SARS-CoV antibodies 2 weeks after discharge; ‡azithromycin, ampicillin/sulbactam, clindamycin, ceftiraxone, ceftriaxone, cefazidime, cefepime, cefpirome, imipenem, meropenem, or teicoplanin; §length of hospital stay for survivors of ARDS; ||length of hospital stay for all survivors.

SARS = severe acute respiratory syndrome; ARDS = acute respiratory distress syndrome; RT-PCR = reverse transcriptase-polymerase chain reaction; SARS-CoV = SARS-coronavirus; HBV = hepatitis B virus; CVA = cerebrovascular accident; HCV = hepatitis C virus; TB = tuberculosis; COPD = chronic obstructive pulmonary disease; IVIG = intravenous immunoglobulin; IQR = interquartile range.

Table 2. Laboratory findings during the hospital course of SARS*

|                      | Non-ARDS, median (IQR) | ARDS, median (IQR) | \(p\) |
|----------------------|------------------------|-------------------|------|
| Lowest leukocyte count (per mm\(^3\)) | 4,050 (3,425–5,425) | 6,300 (4,125–8,600) | 0.012 |
| Lowest lymphocyte count (per mm\(^3\)) | 579 (448–983)         | 359 (372–766)     | 0.003 |
| Lowest platelet count \(\times 10^9\) (per mm\(^3\)) | 152 (120–185) | 131 (85–170)       | 0.068 |
| Highest ALT (IU/L)    | 54 (29–119)           | 66 (33–120)       | 0.818 |
| Highest AST (IU/L)    | 41 (30–88)            | 92 (56–138)       | 0.004 |
| Highest creatine kinase (IU/L) | 54 (23–86) | 138 (56–455)       | < 0.001 |
| Highest LDH (IU/L)    | 257 (200–392)         | 517 (363–758)     | < 0.001 |
| Highest CRP (mg/dL)   | 4.3 (0.7–8.9)         | 12.7 (10.0–23.6)  | < 0.001 |

*Square-root transformation was performed for the normality of data.

SARS = severe acute respiratory syndrome; ARDS = acute respiratory distress syndrome; IQR = interquartile range; ALT = alanine aminotransferase; AST = aspartate aminotransferase; LDH = lactate dehydrogenase; CRP = C-reactive protein.
were 13.71 (95% confidence interval, CI, 1.28–146.86) for patients with concurrent diabetes mellitus, 10.61 (95% CI, 2.08–54.14) for patients older than 65 years, and 8.43 (95% CI, 1.93–36.92) for patients with elevated LDH (Table 4).

### Discussion

Taiwan has had the third largest number of SARS cases, after Hong Kong and China. To date, however, no large, formal analysis of the data from Taiwan can

| Table 3. Radiographic patterns at admission in 67 SARS patients |
|---------------------------------------------------------------|
| **Pattern of involvement**                                    |
| Central | Peripheral | Central and peripheral |
| Non-ARDS (n = 34) | ARDS (n = 33) | Total, n (%) |
| 0       | 13       | 8           |
| 11      | 19       |
| 22 (32.8) | 27 (40.3) |
| **Number of lesions** |
| Unifocal | Multifocal, unilateral | Multifocal, bilateral |
| Non-ARDS (n = 34) | ARDS (n = 33) | Total, n (%) |
| 17       | 17       | 12           |
| 28 (41.8) | 12 (17.9) |
| **Number of involved zones**                                      |
| 1       | 2       | > 2          |
| Non-ARDS (n = 34) | ARDS (n = 33) | Total, n (%) |
| 17       | 13       | 2            |
| 30 (44.8) | 10 (14.9) |
| **Lung zone***                                                                                               |
| Right upper | Right middle | Right lower |
| Non-ARDS (n = 34) | ARDS (n = 33) | Total, n (%) |
| 3       | 4       | 11           |
| 9 (13.4) | 16 (23.9) |
| **Normal radiography** |
| Non-ARDS (n = 34) | ARDS (n = 33) | Total, n (%) |
| 13       | 4       |
| 17 (25.4) |

*Zone height was defined as one-third of the craniocaudal extent of the lungs.

SARS = severe acute respiratory syndrome; ARDS = acute respiratory distress syndrome.

| Table 4. Predictors of ARDS in patients with SARS |
|-------------------------------------------------|
| **Univariate analysis** |
| Odds ratio (95% CI) | p |
| Age > 65 yr | 11.53 (3.28–40.48) | < 0.001 |
| Male gender | 2.82 (1.05–7.60) | 0.04 |
| Leukocyte count > 10,000/mm³ | 3.77 (1.16–12.25) | 0.027 |
| Lymphocyte count < 1,000/mm³ | 2.47 (0.87–7.02) | 0.09 |
| Platelet count < 10⁹/mm³ | 3.29 (0.33–33.35) | 0.313 |
| LDH > 213 IU/L | 9.41 (3.01–29.41) | < 0.001 |
| ALT > 40 IU/L | 1.20 (0.13–3.37) | 0.73 |
| AST > 45 IU/L | 5.24 (1.78–15.42) | 0.003 |
| Creatine kinase > 200 IU/L | 5.89 (0.65–53.45) | 0.115 |
| Diabetes mellitus | 31.04 (3.79–254.19) | 0.001 |
| HBV carrier | 0.37 (0.07–2.08) | 0.262 |
| Hypertension | 4.49 (1.11–18.19) | 0.035 |
| Cerebrovascular accident | 8.88 (1.03–76.69) | 0.047 |

**Multivariate analysis**

| Odds ratio (95% CI) | p |
| Diabetes mellitus | 13.71 (1.28–146.86) | 0.030 |
| Age > 65 yr | 10.61 (2.08–54.14) | 0.005 |
| LDH > 213 IU/L | 8.43 (1.93–36.92) | 0.005 |

ARDS = acute respiratory distress syndrome; SARS = severe acute respiratory syndrome; CI = confidence interval; LDH = lactate dehydrogenase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; HBV = hepatitis B virus.
be found in the English literature. In April 2003, 7 health care workers, including 2 physicians and 3 nurses, died from SARS in Taiwan; most of these workers had worn surgical masks. Initial reports showed that SARS had a high degree of respiratory infectiousness and could possibly be transmitted through airborne infection. Faced with an unknown disease, we experienced much anxiety. Further, our ICU had no negative-pressure design, and to protect staff and patients, treatment was done in negative-pressure isolation rooms with an antechamber; these rooms were usually used for isolation of patients with tuberculosis or acquired immune deficiency syndrome. The transfer of patients from wards for examination required an absolute indication. Bronchoscopy was not recommended for patients with a typical clinical picture and clear epidemiologic link. Anesthesiologists stood by all day to perform intubations for SARS patients. The isolation rooms were guarded by security personnel, and infection control was guided by a team of specialists.

Since our hospital was responsible for the management of critical cases in northern Taiwan, the outcomes shown were more severe than in other medical settings. Initial clinical presentations and laboratory features were similar to those in other series. Symptoms of acute respiratory distress developed in about half of the patients (33/67; 49.3%); 21 of these patients (63.6%) died and the other 12 were discharged from hospital. The risk factors for ARDS were age more than 65 years, diabetes mellitus, and elevated LDH level. Other researchers have also documented independent predictors associated with poor outcomes, e.g. acute illness leading to death; the need for mechanical ventilation; and ICU admission.2

The diagnosis of SARS was based on a comprehensive contact history and precise laboratory tests. The World Health Organization diagnostic criteria for SARS have a reported sensitivity of 26% and specificity of 96%,14 whereas the sensitivity of laboratory testing for SARS-CoV is less than 80%.15 Since contact history has not been reliable after SARS cluster cases were noted in some community groups, one needed to be highly suspicious of any transmission of pneumonia. Our inclusion criteria added a component of transmission of pneumonia, and a high degree of clinical diagnostic accuracy was confirmed by laboratory tests.

Hematologic abnormalities, especially lymphopenia, were common in our cohort, probably because of ribavirin therapy. Intravenous immunoglobulin was given when more severe hematologic abnormalities occurred. Pancytopenia and hemophagocytosis were noted in 2 patients without ARDS. This phenomenon has been noted in other viral infections, and the outcome was fair after supportive treatment.16,17 In our cohort, elevation of AST was more obvious than that of ALT in the ARDS group. Since carriers of hepatitis B virus did not show profound lung injury, whether SARS-CoV will interact with hepatitis B virus is not yet clear.

The location of pulmonary infiltration in SARS patients has been reported to be the peripheral lungs.18,19 In our cohort, initial infiltrative lesions were mainly located in the central and peripheral lungs. The best explanation for this is that anterior and posterior peripheral lesions would be projected to a central location on posteroanterior chest radiograph. The efficacy of treatment was difficult to evaluate because patients usually received a combination of medications, including antiviral, broad-spectrum antibacterial and corticosteroid drugs, in addition to supportive therapy. Initially, because the cause of SARS was thought to be an atypical pathogen, 55 patients (82.1%) received empiric antibacterial therapy with a fluoroquinolone. Levofloxacin was the drug of choice in 49 patients (73.1%) because of its broad-spectrum activity against anaerobic and aerobic Gram-positive and Gram-negative bacteria. In patients who developed ARDS, stronger antibiotics such as fourth-generation cephalosporins, teicoplanin and carbapenems were more often used. There is no proven effective treatment for SARS; hence, there was no difference in the proportion of patients per group who received the antiviral ribavirin, intravenous immunoglobulin, or moderate amounts of corticosteroids. However, pulse corticosteroid therapy was more often used for ARDS than non-ARDS patients.

Our study has several limitations. It was retrospective and had no standard medical chart for following clinical courses. Some important information may, therefore, have been lost, which may have led to bias in the comparison. To date, however, this is the largest clinical analysis of SARS in Taiwan.

References

1. Drazen JM. Case clusters of the severe acute respiratory syndrome. N Engl J Med 2003;348:66–7.
2. Booth CM, Matukas LM, Tomlinson GA, Rachlis AR, Rose DB, Dwosh HA, Walmsley SL, et al. Clinical features and short-term outcomes of 144 patients with SARS in the Greater Toronto Area. JAMA 2003;289:2801–9. [Erratum in: JAMA 2003;290:334.]
3. Tsang KW, Ho PL, Ooi GC, Yee WK, Wang T, Chan-Yeung M, Lam WK, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003;348:1977–85.
4. Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt G, Ahuja A,
et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. *N Engl J Med* 2003;348:1986–94.

5. World Health Organization. *Severe acute respiratory syndrome (SARS).* Available from: http://www.who.int/csr/sars [Date accessed: May 18, 2004.]

6. Twu SJ, Chen TJ, Chen CJ, Olsen SJ, Lee LT, Fisk T, Hsu KH, et al. Control measures for severe acute respiratory syndrome (SARS) in Taiwan. *Emerg Infect Dis* 2003;9:718–20.

7. Centers for Disease Control and Prevention. Update: severe acute respiratory syndrome – Taiwan, 2003. *MMWR Morb Mortal Wkly Rep* 2003;52:461–6.

8. Poutanen SM, Low DE, Henry B, Finkelstein S, Rose D, Green K, Tellier R, et al. Identification of severe acute respiratory syndrome in Canada. *N Engl J Med* 2003;348:1995–2005.

9. Drosten C, Günther S, Preiser W, van der Werf S, Brodt HR, Becker S, Rabenau H, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. *N Engl J Med* 2003;348:1967–76.

10. Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, Tong S, et al. A novel coronavirus associated with severe acute respiratory syndrome. *N Engl J Med* 2003;348:1953–66.

11. Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, Lim W, Nicholls J, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. *Lancet* 2003;361:1319–25.

12. Chiang CH, Chen HM, Shih JF, Su WJ, Perng RP. Management of hospital-acquired severe acute respiratory syndrome with different disease spectrum. *J Chin Med Assoc* 2003;66:328–38.

13. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, et al. The American-European consensus conference on ARDS: definitions, mechanisms, relevant outcomes, and clinical trial coordination. *Am J Respir Crit Care Med* 1994;149:818–24.

14. Rainer TH, Cameron PA, Smit D, Ong KL, Hung AN, Nin DC, Abuja AT, et al. Evaluation of WHO criteria for identifying patients with severe acute respiratory syndrome out of hospital: prospective observational study. *BMJ* 2003;326:1354–8.

15. Poon LL, Wong OK, Chan KH, Luk W, Yuen KY, Peiris JS, Guan Y. Rapid diagnosis of a coronavirus associated with severe acute respiratory syndrome. *Clin Chem* 2003;49:953–5.

16. Falsey AR, Walsh EE, Hayden FG. Rhinovirus and coronavirus infection-associated hospitalizations among older adults. *J Infect Dis* 2002;185:1338–41.

17. El-Sahly HM, Atmar RL, Glezen WP, Greenberg SB. Spectrum of clinical illness in hospitalized patients with ‘common cold’ virus infections. *Clin Infect Dis* 2000;31:96–100.

18. Wong KT, Antonio GE, Hui D, Lee N, Yuen E, Wu A, Leung CB, et al. Severe acute respiratory syndrome: radiographic appearances and pattern progression in 138 patients. *Radiology* 2003;228:401–6.

19. Wong KT, Antonio GE, Hui D, Lee N, Yuen E, Wu A, Leung CB, et al. Thin-section CT of severe acute respiratory syndrome: evaluation of 73 patients exposed to or with the disease. *Radiology* 2003;228:395–400.